{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:27:23Z","timestamp":1778696843944,"version":"3.51.4"},"reference-count":124,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hematopoietic stem cell transplant (HSCT) is now recognized as a standard treatment option for people with HIV (PWH) who develop high-risk hematologic malignancies. However, the involved polypharmacy can lead to complications from drug interactions and toxicities, affecting the efficacy and safety of chemotherapy and antiretroviral therapy (ART). Managing these patients requires a personalized approach, including the careful selection of ART based on previous therapies and potential interactions, alongside risk assessment for infections. This discussion will address the history of HSCT in PWH and management considerations for this group.<\/jats:p>","DOI":"10.3390\/v16101560","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T03:57:52Z","timestamp":1727755072000},"page":"1560","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Management of Hematopoietic Stem Cell Transplant in People with HIV"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-1573","authenticated-orcid":false,"given":"Jana K.","family":"Dickter","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-0177","authenticated-orcid":false,"given":"Courtney Moc","family":"Willeford","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, City of Hope National Medical Center, Duarte, CA 91010, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/j.bbmt.2019.03.021","article-title":"Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection","volume":"25","author":"Arslan","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803\/AMC 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.bbmt.2019.06.033","article-title":"Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903\/AMC-080 Trial","volume":"25","author":"Ambinder","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/cid\/ciy010","article-title":"Epidemiology and Outcomes of Hematopoietic Stem Cell Transplantation in Human Immunodeficiency Virus-Positive Patients From 1998 to 2012: A Nationwide Analysis","volume":"67","author":"Mehta","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood.2020005469","article-title":"Hematologic cancers in individuals infected by HIV","volume":"139","author":"Carbone","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-Associated Cancers and Related Diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/BLCTT.S361320","article-title":"HIV\/AIDS Associated Lymphoma: Review","volume":"12","author":"Berhan","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/asheducation-2013.1.389","article-title":"Transplantation in HIV-infected subjects: Is cure possible?","volume":"2013","author":"Zaia","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_9","unstructured":"U.S. Department of Health and Human Services (2024, July 16). Aging with HIV. Published 2021. Updated 6\/4\/2024, Available online: https:\/\/www.hiv.gov\/hiv-basics\/living-well-with-hiv\/taking-care-of-yourself\/aging-with-hiv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003","volume":"148","author":"Patel","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: A population-based, registry-linkage study","volume":"4","author":"Shiels","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/QAD.0000000000000071","article-title":"Malignancies in HIV\/AIDS: From epidemiology to therapeutic challenges","volume":"28","author":"Rubinstein","year":"2014","journal-title":"Aids"},{"key":"ref_15","first-page":"660","article-title":"Non-AIDS-defining cancers","volume":"22","author":"Mitsuyasu","year":"2014","journal-title":"Top. Antivir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s11908-014-0406-0","article-title":"Non-AIDS-Defining Malignancies in the HIV-Infected Population","volume":"16","author":"Wang","year":"2014","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Isaguliants, M., Bayurova, E., Avdoshina, D., Kondrashova, A., Chiodi, F., and Palefsky, J.M. (2021). Oncogenic Effects of HIV-1 Proteins, Mechanisms Behind. Cancers, 13.","DOI":"10.3390\/cancers13020305"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbmt.2010.03.019","article-title":"HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)","volume":"16","author":"Krishnan","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2013.089052","article-title":"Stem cell mobilization in HIV seropositive patients with lymphoma","volume":"98","author":"Re","year":"2013","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Balsalobre","year":"2009","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.clml.2023.05.006","article-title":"Comparison of Inpatient Outcomes Between HIV Positive and Negative Hospitalizations for Autologous Stem Cell Transplant Treatment among Lymphoid Malignancies","volume":"23","author":"Ruiz","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/QCO.0000000000001022","article-title":"Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV","volume":"37","author":"Rubinstein","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1016\/S2352-3018(20)30117-X","article-title":"Haemopoietic cell transplantation in patients living with HIV","volume":"7","author":"Ambinder","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbmt.2018.03.009","article-title":"Impact of HIV Infection on Transplant Outcomes after Autologous Peripheral Blood Stem Cell Transplantation: A Retrospective Study of Japanese Registry Data","volume":"24","author":"Yoshinaga","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41409-020-0846-0","article-title":"Autologous stem cell transplantation for lymphoma in HIV+ patients: Higher rate of infections compared with non-HIV lymphoma","volume":"55","author":"Balsalobre","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1080\/10428190600658688","article-title":"Presentation and outcomes of systemic non-Hodgkin\u2019s lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS","volume":"47","author":"Diamond","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1080\/1042819021000006402","article-title":"Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma","volume":"43","author":"Navarro","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.21759","article-title":"Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial","volume":"106","author":"Weiss","year":"2006","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.2001.02656.x","article-title":"Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin\u2019s lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone","volume":"112","author":"Navarro","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_31","unstructured":"(2024, July 16). Gilead Sciences VEMLIDY (Tenofovir Alafenamide) [Package Insert]. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/liver-disease\/vemlidy\/vemlidy_pi.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_33","unstructured":"Bristol-Myers Squibb Company (2024, July 16). BARACLUDE (Entecavir) Tablets, for Oral Use [Package Insert]. Available online: https:\/\/packageinserts.bms.com\/pi\/pi_baraclude.pdf."},{"key":"ref_34","unstructured":"(2024, July 11). Clinicalinfo.HIV.gov. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Marin, R.C., Behl, T., Negrut, N., and Bungau, S. (2021). Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir\/Ritonavir or Darunavir\/Cobicistat. Biomedicines, 9.","DOI":"10.3390\/biomedicines9030313"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1120009X.2021.1940436","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants","volume":"34","author":"Flammang","year":"2022","journal-title":"J. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"Aids"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/QAI.0000000000002888","article-title":"Brief Report: Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Efficacy in Participants with Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials","volume":"89","author":"Andreatta","year":"2022","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/hiv.13376","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in patients with genotypic NRTI resistance","volume":"24","author":"Shafran","year":"2023","journal-title":"HIV Med."},{"key":"ref_41","unstructured":"(2024, July 16). Genentech, Inc. and Alexion Pharmaceuticals, Inc. FUZEON (Enfuvirtide) for Injection [Package Insert]. Available online: https:\/\/www.gene.com\/download\/pdf\/fuzeon_prescribing.pdf."},{"key":"ref_42","unstructured":"TaiMed Biologics USA Corp (2024, July 16). TROGARZO (Ibalizumab-Uiyk) Injection [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761065lbl.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jcpt.13411","article-title":"Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report","volume":"46","author":"Dickter","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_44","unstructured":"(2024, July 16). Pfizer Labs SELZENTRY (Maraviroc) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022128s002lbl.pdf."},{"key":"ref_45","unstructured":"(2024, July 16). ViiV Healthcare RUKOBIA (Fostemsavir) Extended-Release Tablet [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212950s000lbl.pdf."},{"key":"ref_46","unstructured":"(2024, July 16). Gilead Sciences SUNLENCA (lenacapavir) [Package Insert]. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf."},{"key":"ref_47","unstructured":"Astellas Pharma US, Inc. (2024, July 16). CRESEMBA (Isavuconazonium Sulfate) [Package Insert]. Available online: https:\/\/www.astellas.us\/docs\/cresemba.pdf."},{"key":"ref_48","unstructured":"Merck and Company, Inc. (2024, July 16). NOXAFIL (Posaconazole) [Package Insert]. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/n\/noxafil\/noxafil_ppi.pdf."},{"key":"ref_49","unstructured":"Pfizer, Inc. (2024, July 16). VFEND (Voriconazole) [Package Insert]. Available online: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12292."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/17425255.2014.883379","article-title":"Clinically relevant drug-drug interactions between antiretrovirals and antifungals","volume":"10","author":"Vadlapatla","year":"2014","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_51","unstructured":"Accord Healthcare Inc. (2024, July 16). Cyclophosphamide Injection [Package Insert]. 20202. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00067461.PDF."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","article-title":"Protease inhibitors potentiate chemotherapy-induced neutropenia","volume":"104","author":"Bower","year":"2004","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007691-200002000-00006","article-title":"Pharmacokinetics and metabolism of sirolimus","volume":"22","author":"Trepanier","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"ref_54","unstructured":"Astellas Pharma US, Inc. (2024, July 16). PROGRAF (Tacrolimus) Capsules [Package Insert]. Available online: https:\/\/www.astellas.us\/docs\/prograf.pdf."},{"key":"ref_55","unstructured":"Novartis Pharmaceuticals Corporation (2024, July 16). NEORAL (Cyclosporine) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027,050716s028lbl.pdf."},{"key":"ref_56","unstructured":"Pfizer, Inc. (2024, July 16). RAPAMUNE (Sirolimus) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021083s059,021110s076lbl.pdf."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Yang, Y., Li, P., Zhang, Z., Wang, Z., Liu, L., and Liu, X. (2020). Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197023"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00003088-200443120-00004","article-title":"Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools","volume":"43","author":"Sankatsing","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-018-3929-z","article-title":"Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome","volume":"34","author":"Schijvens","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","unstructured":"Kadmon Pharmaceuticals, LLC. (2024, July 16). REZUROCK (Belumosudil) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214783s000lbl.pdf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpdd.1082","article-title":"A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered with CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_64","unstructured":"(2024, July 16). ViiV Healthcare Retrovir (Zidovudine) [Package Insert], Available online: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/RETROVIR-PI%20dated%20June%202023.PDF."},{"key":"ref_65","unstructured":"(2024, July 16). ViiV Healthcare EPIVIR (Lamivudine) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020564s37_020596s036lbl.pdf."},{"key":"ref_66","unstructured":"(2024, July 16). Gilead Sciences EMTRIVA (Emtricitabine) [Package Insert]. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/emtriva\/emtriva_pi.pdf."},{"key":"ref_67","unstructured":"(2024, July 16). ViiV Healthcare ZIAGEN (Abacavir Sulfate) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020977s024,020978s028lbl.pdf."},{"key":"ref_68","unstructured":"(2024, July 16). Gilead Sciences VIREAD (Tenofovir Disoproxil Fumarate) Tablets [Package Insert]. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/viread\/viread_pi.pdf."},{"key":"ref_69","unstructured":"(2024, July 16). Bristol-Myers Squibb SUSTIVA (Efavirenz) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020972s049-021360s038lbl.pdf."},{"key":"ref_70","unstructured":"(2024, July 16). Cipla LTD Nevirapine [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/pepfar\/202212PI.pdf."},{"key":"ref_71","unstructured":"(2024, July 16). Janssen Products, LP INTELENCE (Etravirine) [Package Insert]. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/INTELENCE-pi.pdf."},{"key":"ref_72","unstructured":"(2024, July 16). Janssen Products, LP EDURANT (Rilpivirine) [Package Insert]. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/EDURANT-pi.pdf."},{"key":"ref_73","unstructured":"Merck & Co., Inc. (2024, July 16). PIFELTRO (Doravirine) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210806s007lbl.pdf."},{"key":"ref_74","unstructured":"Janssen Pharmaceuticals, Inc. (2024, July 16). PREZISTA (Darunavir) [Package Insert), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021976s021lbl.pdf."},{"key":"ref_75","unstructured":"(2024, July 16). Gilead Sciences TYBOST (Cobicictat) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203094s008lbl.pdf."},{"key":"ref_76","unstructured":"AbbVie Inc. (2024, July 16). NORVIR (Ritonavir) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf."},{"key":"ref_77","unstructured":"(2024, July 16). Gilead Sciences STRBILD (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) [Package Insert], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203100s030lbl.pdf."},{"key":"ref_78","unstructured":"(2024, July 16). Merck and Company, Inc. ISENTRESS (Raltegravir) [Package Insert]. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf."},{"key":"ref_79","unstructured":"(1982, March 16). ViiV Healthcare TIVICAY (Dolutegravir) [Package Insert], Available online: https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/dolutegravir-tivicay-package-insert."},{"key":"ref_80","unstructured":"(2024, July 16). Gilead Sciences BIKTARVY (Bictegravir, Emtricitabine, Tenofovir Alafenamide) [Package Insert]. Available online: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/biktarvy\/biktarvy_pi.pdf."},{"key":"ref_81","unstructured":"(2024, July 16). ViiV Healthcare VOCABRIA (Cabotegravir) [Package Insert]. Available online: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Vocabria\/pdf\/VOCABRIA-PI-PIL.PDF."},{"key":"ref_82","unstructured":"(2024, July 16). Clinicalinfo.HIV.gov. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/whats-new."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JOP.18.00366","article-title":"Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary","volume":"14","author":"Taplitz","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1001\/jama.2023.4899","article-title":"Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement","volume":"329","author":"Mangione","year":"2023","journal-title":"JAMA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1086\/503917","article-title":"The risk of tuberculosis in patients with cancer","volume":"42","author":"Kamboj","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/383307","article-title":"Mycobacterial infection: A difficult and late diagnosis in stem cell transplant recipients","volume":"38","author":"Cordonnier","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis (1982). Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull. World Health Organ., 60, 555\u2013564."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4046\/trd.2017.0052","article-title":"Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy","volume":"81","author":"Kim","year":"2018","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_90","first-page":"20499361211039050","article-title":"Fungal infections in hematopoietic stem-cell transplant patients: A review of epidemiology, diagnosis, and management","volume":"8","author":"Rahi","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: A 6-year retrospective study","volume":"36","author":"Neuville","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ejh.14133","article-title":"Late-onset Pneumocystis jirovecii pneumonia post-allogeneic stem cell transplantation after time-dependent discontinuation of prophylaxis","volume":"112","author":"Stavi","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1038\/emi.2016.18","article-title":"Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients","volume":"5","author":"Chan","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S1473-3099(23)00495-4","article-title":"Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: Guidelines from the 9th European Conference on Infections in Leukaemia, 2022","volume":"24","author":"Aerts","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-3046.2006.00622.x","article-title":"Nitazoxanide or CD3+\/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant?","volume":"11","author":"Faraci","year":"2007","journal-title":"Pediatr. Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bmt.2010.156","article-title":"Cryptosporidium parvum infection vs GVHD after hematopoietic SCT: Diagnosis by PCR with resolution of symptoms","volume":"46","author":"McDonald","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1097\/01.TP.0000121806.42836.45","article-title":"Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation","volume":"77","author":"Zeiser","year":"2004","journal-title":"Transplantation"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bmt.2010.200","article-title":"Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: A prospective single centre study","volume":"46","author":"Legrand","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e12826","DOI":"10.1111\/tid.12826","article-title":"Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of Cryptosporidium oocysts by intestinal biopsies","volume":"20","author":"Kagawa","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Kaminskiy, Y., Ganeeva, I., Chasov, V., Kudriaeva, A., and Bulatov, E. (2024). Asymmetric T-cell division: Insights from cutting-edge experimental techniques and implications for immunotherapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1301378"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"ofac385","DOI":"10.1093\/ofid\/ofac385","article-title":"Disseminated Mycobacterium avium Complex Myositis in a Patient with Graft-Versus-Host Disease","volume":"9","author":"Kompa","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1702330","DOI":"10.1183\/13993003.02330-2017","article-title":"Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant","volume":"51","author":"Hirama","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bbmt.2017.09.015","article-title":"Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation","volume":"24","author":"Beswick","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/420746","article-title":"Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients","volume":"38","author":"Doucette","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies","volume":"13","author":"Jakharia","year":"2021","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02337-18","article-title":"Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1086\/511859","article-title":"Zoonoses in Solid-Organ and Hematopoietic Stem Cell Transplant Recipients","volume":"44","author":"Kotton","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5500\/wjt.v11.i6.244","article-title":"Bartonellosis in transplant recipients: A retrospective single center experience","volume":"11","author":"Pischel","year":"2021","journal-title":"World J. Transplant."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Denning, D.W., and Morgan, E.F. (2022). Quantifying Deaths from Aspergillosis in HIV Positive People. J. Fungi, 8.","DOI":"10.3390\/jof8111131"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e14175","DOI":"10.1111\/tid.14175","article-title":"Challenges in management of invasive fungal infections in stem cell transplant","volume":"25","author":"Walker","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.bbmt.2014.06.001","article-title":"Clostridium difficile infection in the hematopoietic unit: A meta-analysis of published studies","volume":"20","author":"Zacharioudakis","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2019.06.021","article-title":"Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population","volume":"25","author":"Morrisette","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/LGT.0000000000000468","article-title":"Guidelines for Cervical Cancer Screening in Immunosuppressed Women without HIV Infection","volume":"23","author":"Moscicki","year":"2019","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciac044","article-title":"Anal Cancer Screening and Prevention: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Guidelines","volume":"74","author":"Barroso","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_116","unstructured":"Hirsch, B., Fine, S.M., Vail, R., McGowan, J.P., Merrick, S.T., Radix, A., Hoffmann, C.J., and Gonzalez, C.J. (2024, July 16). Screening for Anal Dysplasia and Cancer in Adults With HIV, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556472\/."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually Transmitted Infections Treatment Guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Saling, C.F., Gea-Banacloche, J., Trickett, J.S., and Blair, J.E. (2021). Coccidioidomycosis in Allogeneic Stem Cell Transplant Recipients: Case Series and Review of the Literature. J. Fungi, 7.","DOI":"10.3390\/jof7050339"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"ofx041","DOI":"10.1093\/ofid\/ofx041","article-title":"Pulmonary Histoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Review of the Literature","volume":"4","author":"Natarajan","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_121","first-page":"8124137","article-title":"Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis","volume":"2020","author":"Agrawal","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e14109","DOI":"10.1111\/tid.14109","article-title":"Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy","volume":"25","author":"Reynolds","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_123","unstructured":"(2024, September 25). Centers for Disease Control and Prevention Immunization Schedules, Available online: https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/adult-age.html."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.296.7.815","article-title":"Biology of CCR5 and Its Role in HIV Infection and Treatment","volume":"296","author":"Lederman","year":"2006","journal-title":"JAMA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1560\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:08:15Z","timestamp":1760112495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":124,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["v16101560"],"URL":"https:\/\/doi.org\/10.3390\/v16101560","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}